Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

The Tarsounas group publish two outstanding papers

Publication Research

Madalena Tarsounas' group have recently published two new papers in EMBO Molecular Medicine and Nature Communications.

The Tarsounas group, Department of Oncology

In Tacconi et al . they discovered that chlorambucil, an alkylating agent in clinical use for the treatment of leukemia, has a high therapeutic potential against BRCA1/2-mutated tumours. Importantly, while being equally effective as cisplatin against this tumour subset, chlorambucil showed significantly lower overall toxicity.

Find the original publication here:

https://www.embopress.org/lookup/doi/10.15252/emmm.201809982

 

In Reisländer et al. they demonstrated that loss of BRCA2 leads to activation of the cGAS-STING pathway which results in a cell-intrinsic type I interferon response. Importantly, this innate immune response in BRCA2-deficient cells is potentiated by treatment with PARP inhibitors.

Find the original publication here:

https://www.nature.com/articles/s41467-019-11048-5

 

Similar stories

Multi-cancer blood test shows real promise in NHS trial

An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.

The Howat Foundation to fund Chair in Clinical Oncology

Oxford Cancer announce the endowment of a Chair in Clinical Oncology, thanks to generous philanthropic support from The Howat Foundation

New Oxford and Nottingham developed tool uses existing health records to predict people’s risk of developing lung cancer within the next 10 years

A team of researchers from the University of Oxford and the University of Nottingham have developed a new tool, called ‘CanPredict’, aimed at identifying the people most at risk of developing lung cancer over the next 10 years, and put them forward for screening tests earlier, saving time, money and, most importantly, lives.

Scientists find genetic ‘marker’ linked to serious side-effects from skin cancer treatment

New research from the Fairfax Group has identified a genetic marker that could be used to predict a patient’s risk of developing serious side-effects when undergoing immunotherapy treatment for metastatic melanoma.

Oxford gets £122m funding for healthcare research

Health and care research in Oxford is to receive £122 million in government funding over the next five years to improve diagnosis, treatment and care for NHS patients. The funding was awarded to the city’s two National Institute for Health and Care Research (NIHR) Biomedical Research Centres (BRC).

The Department represented at the European Radiation Research Society annual conference

Researchers from the Department of Oncology attend the prestigious European Radiation Research Society (ERRS) in annual conference in Catania, Italy to present their research in Radiation Oncology.